Search
Dolutegravir
go.drugbank.com/drugs/DB08930ApprovedInvestigational[A31342] Dolutegravir was developed by ViiV Healthcare and FDA-approved on August 12, 2013. … [A7514] The effect of this drug has no homology in human host cells, which gives it excellent tolerability and minimal toxicity.
Benzoic acid
go.drugbank.com/drugs/DB03793ApprovedInvestigationalTotal Positive and Negative Syndrome Scale scores dropped by 21% compared to placebo. … As the sodium salt form, sodium benzoate is used as a treatment for urea cycle disorders due to its ability to bind amino acids.
Mixtures: POLY-N OINTMENT, NEO BOROCILLINAProducts: Seo Jeong Ho Hwang Chill Mist, Seo Jeong Ho Hwang Chill DeodorantClonazepam
go.drugbank.com/drugs/DB01068ApprovedIllicitInvestigationalNow available as a generic medication, the agent continues to see exceptionally high use as millions of prescriptions are written for the medication internationally every year. … [FDA Label][A175438,L5572,F3763,F3787,F3796] The mechanism of action appears to involve the enhancement of gamma-aminobutyric acid receptor responses.
Synonyms: 5-(o-chlorophenyl)-7-nitro-1,3-dihydro-2H-1,4-benzodiazepin-2-oneProducts: Co ClonazepamEfanesoctocog alfa
go.drugbank.com/drugs/DB16662ApprovedInvestigationalEndogenous VWF protects FVIII from degradation but also sets a half-life of approximately 15 to 19 h. … [A257464,A257469] In February 2023, efanesoctocog alfa was approved by the FDA as a new class of factor VIII therapy for hemophilia A.[L45379,L45414]
Rilzabrutinib
go.drugbank.com/drugs/DB17709ApprovedInvestigationalRilzabrutinib is an oral, reversible, covalent inhibitor of Bruton's tyrosine kinase [A259078, L53738] that was approved by the FDA on August 29, 2025, for the treatment of persistent and chronic immune … Rilzabrutinib is thought to work by dual mechanisms of action in ITP: It attenuates macrophage (Fcγ receptor)-mediated platelet destruction and reduces the production of pathogenic autoantibodies.
Anisotropine methylbromide
go.drugbank.com/drugs/DB00517ApprovedIts use as treatment adjunct in peptic ulcer has been replaced by the use of more effective agents. … action on the bile ducts and gallbladder.
Sotalol
go.drugbank.com/drugs/DB00489ApprovedInvestigational[A178579] Sotalol was first approved as an oral tablet on 30 October 1992.
Categories: Beta Blocking Agents, Non-Selective, Beta Blocking Agents, Non-Selective, and ThiazidesProducts: Co SotalolTelisotuzumab vedotin
go.drugbank.com/drugs/DB15104ApprovedInvestigational[L53193] Telizotuzumab vedotin-tllv was approved by the US FDA in May 2025 for previously treated advanced NSCLC patients with high c-Met protein overexpression,[L53158,L53183] becoming the first treatment … [L53158] The c-Met protein is found to be overexpressed in approximately 25% of advanced EGFR wild type, non-squamous NSCLC patients and is associated with poor prognosis and limited treatment options.
Vildagliptin
go.drugbank.com/drugs/DB04876ApprovedInvestigational[A232488] By inhibiting DPP-4, vildagliptin prevents the degradation of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which are incretin hormones that promote … [A232488] Oral vildagliptin was approved by the European Medicines Agency in 2008 for the treatment of type II diabetes mellitus in adults as monotherapy or in combination with [metformin], a sulfonylurea
Glycine
go.drugbank.com/drugs/DB00145ApprovedInvestigationalNutraceuticalVet approvedA non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.
Mixtures: Vamin N, AMINOSTERIL N-HEPA 8%